NasdaqGS - Delayed Quote USD

Tilray Brands, Inc. (TLRY)

1.7200 -0.0100 (-0.58%)
At close: April 22 at 4:00 PM EDT
1.7200 0.00 (0.00%)
After hours: April 22 at 7:59 PM EDT
Loading Chart for TLRY
DELL
  • Previous Close 1.7300
  • Open 1.7400
  • Bid 1.7100 x 15400
  • Ask 1.7400 x 21500
  • Day's Range 1.6500 - 1.7700
  • 52 Week Range 1.5000 - 3.4000
  • Volume 22,627,965
  • Avg. Volume 29,545,495
  • Market Cap (intraday) 1.331B
  • Beta (5Y Monthly) 2.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4400
  • Earnings Date Apr 8, 2024 - Apr 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.36

Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

www.tilray.com

1,600

Full Time Employees

May 31

Fiscal Year Ends

Recent News: TLRY

Related Videos: TLRY

How cannabis stocks can win big with new policy changes

Cannabis legalization has been an issue on many ballots in the past decade, with several states opening up to recreational use legalization. US Vice President Kamala Harris called on the federal government to move "as quickly as possible" in terms of reclassifying cannabis from its current Schedule I classification. If any efforts are successful in doing so, what would the cannabis market look like and who would stand to benefit the most? Poseidon Co-Founder & Managing Partner Emily Paxhia joins Market Domination to give insight into potential new legislation around cannabis and what investors and consumers alike can expect moving forward. Paxhia outlines the current efforts to change cannabis legislation in the US: "Importantly with cannabis legalization, we have several efforts running down the field. There is the rescheduling efforts, and we are hoping to see something come out of that soon. There's also the continued and loud discussions around banking reform in the legislative branch but we've also introduced a path through the judicial branch working with Boies Schiller Flexner [LLP] to challenge the 2004-2005 case on Raich Vs Gonzales which about the Commerce Clause."She continues by affirming: "Interestingly things that are catalytic that change the volume of capital flowing into the industry are very top down. We hear from investors that are paying attention to these federal reform signals, but what we are also really interested in is the state-to-state catalysts that really actually open up the markets and improve the business fundamentals." For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino

Performance Overview: TLRY

Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TLRY
25.22%
S&P 500
5.05%

1-Year Return

TLRY
25.22%
S&P 500
21.22%

3-Year Return

TLRY
89.77%
S&P 500
20.06%

5-Year Return

TLRY
96.49%
S&P 500
72.48%

Compare To: TLRY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TLRY

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    1.34B

  • Enterprise Value

    1.59B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.66

  • Price/Book (mrq)

    0.40

  • Enterprise Value/Revenue

    2.15

  • Enterprise Value/EBITDA

    -12.41

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -47.35%

  • Return on Assets (ttm)

    -1.67%

  • Return on Equity (ttm)

    -9.69%

  • Revenue (ttm)

    743.25M

  • Net Income Avi to Common (ttm)

    -351.95M

  • Diluted EPS (ttm)

    -0.4400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    225.86M

  • Total Debt/Equity (mrq)

    14.41%

  • Levered Free Cash Flow (ttm)

    -14.88M

Research Analysis: TLRY

Analyst Price Targets

1.90
2.36 Average
1.7200 Current
4.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: TLRY

Fair Value

1.7200 Current
 

Dividend Score

0 Low
TLRY
Sector Avg.
100 High
 

Hiring Score

0 Low
TLRY
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
TLRY
Sector Avg.
100 High
 

Research Reports: TLRY

  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, Fair Isaac's upside fair; Initiating Coverage of GE Vernova; and US cable valuations have tumbled perhaps more than deserved; and Marvell Technology, Tilray Brands, and Yum China.

     
  • Analyst Report: Tilray Brands, Inc.

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

    Rating
    Price Target
     
  • Analyst Report: Tilray Brands, Inc.

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.

    Rating
    Price Target
     
  • Analyst Report: Tilray Brands, Inc.

    Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.

    Rating
    Price Target
     

People Also Watch